Trial Profile
Impact of using Using Electronic Health Record (EHR) or Administrative Healthcare Claims Data for time to last treatment administration (TTLA) of Trastuzumab Emtansine (T-DM1)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Sep 2017
Price :
$35
*
At a glance
- Drugs Trastuzumab emtansine (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 19 Sep 2017 New trial record
- 30 Aug 2017 Results presented at the 33rd International Conference on Pharmacoepidemiology and Therapeutic Risk Management